Edition:
India

Deinove SA (ALDEI.PA)

ALDEI.PA on Paris Stock Exchange

0.64EUR
10 Dec 2019
Change (% chg)

€0.02 (+3.23%)
Prev Close
€0.62
Open
€0.62
Day's High
€0.65
Day's Low
€0.62
Volume
61,800
Avg. Vol
47,620
52-wk High
€1.90
52-wk Low
€0.55

Latest Key Developments (Source: Significant Developments)

Deinove Emmanuel Petiot Will Resign As CEO
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Deinove SA ::EVOLUTION IN DEINOVE'S GOVERNANCE.EMMANUEL PETIOT WILL RESIGN AS CHIEF EXECUTIVE OFFICER ("CEO") AS OF DECEMBER 31, 2019.DR. CHARLES WOLER, CHAIRMAN OF THE BOARD OF DIRECTORS, WILL ACT AS INTERIM CEO PENDING THE APPOINTMENT OF A NEW CEO.BOARD OF DIRECTORS HAS CO-OPTED EMMANUEL PETIOT AS A DIRECTOR TO REPLACE BERNARD FANGET, WHO HAS RESIGNED..  Full Article

Deinove H1 Consolidated Loss Widens To 5.4 Million Euros
Thursday, 26 Sep 2019 

Sept 26 (Reuters) - DEINOVE SA ::H1 OPERATING REVENUE EUR 0.4 MILLION VERSUS EUR 0.7 MILLION YEAR AGO.H1 CONSOLIDATED LOSS EUR 5.4 MILLION VERSUS LOSS OF EUR 3.7 MILLION YEAR AGO.H1 OPERATING LOSS EUR 6.2 MILLION VERSUS LOSS OF EUR 4.4 MILLION YEAR AGO.AT JUNE 30, 2019, GROUP'S NET FINANCIAL POSITION WAS AT +€1.9M COMPARED WITH +€3.9M AT JAN 1, 2019.  Full Article

Deinove To Start Phase II Clinical Trial For DNV3837
Thursday, 16 May 2019 

May 16 (Reuters) - Deinove SA ::DEINOVE IS NOW READY TO START PHASE II CLINICAL TRIAL FOR ITS ANTIBIOTIC COMPOUND DNV3837.PRODUCTION OF FIRST COMMERCIAL BATCH OF DNV3837 HAS BEEN SUCCESSFULLY INITIATED.THIS TRIAL WILL BE CONDUCTED AS PART OF AN ACTIVE INVESTIGATIONAL NEW DRUG (IND) AUTHORIZATION AND A RECENTLY UPDATED VERSION OF CLINICAL PROTOCOL.INCLUSION OF FIRST PATIENT IS PLANNED FOR MID-2019.  Full Article

Novel Antibiotics: Deinove Signs Agreement With Institut Pasteur
Tuesday, 9 Apr 2019 

April 9 (Reuters) - DEINOVE SA ::NOVEL ANTIBIOTICS: DEINOVE SIGNS AN AGREEMENT WITH THE INSTITUT PASTEUR TO EXPLORE THE POTENTIAL OF NEW TARGETED STRAINS.  Full Article

Deinove Signs License Option Agreement With Redx Pharma
Thursday, 22 Mar 2018 

March 22 (Reuters) - DEINOVE SA ::DEINOVE EXPANDS ITS INNOVATIVE ANTIBIOTIC PORTFOLIO BY SIGNING A LICENSE OPTION AGREEMENT WITH REDX PHARMA.PROGRAM DEVELOPED BY REDX PHARMA FOCUSES ON A NEW CLASS OF ANTIBIOTICS AIMED AT TREATING MOST LETHAL INFECTIONS.DEINOVE ACQUIRES AN OPTION FOR A LICENSE ON A SERIES OF MOLECULES ABOUT TO ENTER PRECLINICAL DEVELOPMENT..REDX PHARMA ENTRUSTS DEINOVE WITH NEXT STEPS TO OPTIMIZE ITS ANTI-INFECTIVE PROGRAM..  Full Article

Deinove Collaborates With Naicons On Antibiotics Project
Thursday, 8 Mar 2018 

March 8 (Reuters) - DEINOVE SA ::COLLABORATES WITH NAICONS TO DISCOVER NEW ANTIBIOTICS IN THE FRAME OF THE AGIR PROJECT‍​.AS 1ST STEP, WILL HAVE ACCESS TO 400 STRAINS CAREFULLY SELECTED FOR THEIR POTENTIAL.WILL USE ROBOTIC TECHNOLOGY PLATFORM TO DETECT AND CHARACTERIZE ANTIBIOTIC ACTIVITIES OF THESE STRAINS.IN CASE OF DISCOVERY OF STRAIN OF INTEREST, CO MAY ACQUIRE IT EITHER VIA COMMERCIAL LICENSE OR IN FULL OWNERSHIP.POTENTIAL ACQUISITION OF A STRAIN WOULD BE TO INITIATE DEVELOPMENT OF DRUG CANDIDATES.  Full Article